Analysis of allogenic stem cell transplantation for primary immunodeficiency using TRUMP data
Not Applicable
- Conditions
- Primary immunodeficiency
- Registration Number
- JPRN-UMIN000033911
- Lead Sponsor
- Tokyo Medical and Dental University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 800
Inclusion Criteria
Not provided
Exclusion Criteria
The patients whose TRUMP data are insufficient for analysis.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival/ event-free survival in patients with PID after HCT
- Secondary Outcome Measures
Name Time Method We divide the patients into following subgroups; different periods of years, disease categories according to International Union of Immunological Societies; IUIS classification, pre-HCT status of complications; infection, autoimmune disease or autoinflammatory diseases, conditioning regimen; myeloablative, reduced intensity or nothing, and donor sources. We analyze survival, adverse events and long-term immunological reconstitution (i.e. post-transplant chimerism and secession of immunoglobulin supplementation) in each subgroup. In addition, we identify the factors contributing to survival by multivariate analysis, as well as the risks for post-HCT adverse events such as graft-versus host disease, infection or the late complications.